Methodological and preanalytical evaluation of a RAGE immunoassay

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 2075-2078

  Wittwer, Christin ^a   Lehner, Julia ^a   Fersching, Debora ^a   Siegele, Barbara ^a   Stoetzer, Oliver J ^b   Holdenrieder, Stefan ^a,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Hematology/Oncology Outpatient Center Munich   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

ELISA test; Immunoassay; Preanalytics; RAGE; Serum; Stability

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CITRIC ACID; EDETIC ACID; HEPARIN;

ARTICLE; BLOOD SAMPLING; CARBOHYDRATE ANALYSIS; FREEZE THAWING; HUMAN; IMMUNOASSAY; PRIORITY JOURNAL; STORAGE TEMPERATURE;

BLOOD PRESERVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; RECEPTORS, IMMUNOLOGIC;

EID: 84861521571     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28: 367-388, 2010.
2. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM and Nawroth PP: Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83: 876-886, 2005. (Pubitemid 41598688)
3. Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, Rutledge R, Lin B, Amoscato AA, Zeh HJ and Lotze MT: RAGE (receptor for advanced glycation end products), RAGE ligands and their role in cancer and inflammation. J Transl Med 7: 17, 2009.
4. Creagh-Brown BC, Quinlan GJ, Evans TW and Burke-Gaffney A: The RAGE axis in systemic inflammation, acute lung injury and myocardial dysfunction: an important therapeutic target? Intensive Care Med 36: 1644-1656, 2010.
5. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T and Yamamoto H: Novel splice variants of the receptor for advanced glycation end products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370: 1097-1109, 2003. (Pubitemid 36399105)
6. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P and Bianchi ME: A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22: 3716-3727, 2008.
7. Yamagishi S and Matsui T: Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci 2: 1184-1195, 2010.
8. Tan KC, Shiu SW, Chow WS, Leng L, Bucala R and Betteridge DJ: Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49: 2756-2762, 2006.
9. Jing R, Cui M, Wang J and Wang H: Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 57: 55-61, 2010.
10. Brown LF and Fraser CG: Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem 45: 518-519, 2008.
11. Holdenrieder S, Mueller S and Stieber P: Stability of nucleosomal DNA fragments in serum. Clin Chem 51: 1026-1029, 2005. (Pubitemid 40740887)